AIQ Solutions

Join AIQ Solutions on Sunday for our poster presentations at .

AIQ Co-Founder and CSO will be speaking about AI-Based Quantitative Imaging Biomarkers at the Prostate Cancer Foundation Retreat.

Click on the link to register today for our upcoming panel discussion with ESSA Pharma and Xcovery: https://shorturl.at/pqAM0

AIQ is pleased to announce acceptance for publication of their manuscript on deep learning-based organ segmentation models which demonstrates robust performance across a variety of CT scanner manufacturers and models. Click to read more: https://iopscience.iop.org/article/10.1088/2057-1976/acfb06/meta

In light of October being Breast Cancer Awareness Month, we'd like to highlight the collaboration between AIQ and GE HealthCare. Their PET/CT tracer, Cerianna, reveals whole-body ER+ lesion status in patients with recurrent or metastatic breast cancer. Click here to see the abstract presented at https://www.aiq-services.com/wp-content/uploads/2023/09/Automated-Lesion-Detection-for-18F-Fluoroestradiol-PETCT-Images.pdf

Molecular Imaging is used beyond diagnostics but also for therapy selection and optimization. AIQ is thrilled to join the peers from the Society of Nuclear Medicine and Molecular ImagingSNMMI to bring forth more information from the images. Celebrate to raise awareness of how nuclear medicine and molecular imaging are saving lives.

Eric will be presenting AIQ Solutions at the MedInvest Medtech, AI, and Digital Health Conference this week.

The National Cancer Institute (NCI) has awarded AIQ a $2M SBIR grant to develop predictive algorithms for both treatment effectiveness and toxicity for theranostics. This research builds on our very popular commercial products supporting theranostic treatment decision making.

The Society of Nuclear Medicine and Molecular Imaging Therapeutics Conference is off to a great start! Stop by Booth 30 to talk with Dr. Weisman and Clover Ye from AIQ.

AIQ is at the Society of Nuclear Medicine and Molecular Imaging Fall Therapeutics Conference today through this weekend. We will be at Exhibit 30 - stop by to say hi!

AIQ Solutions is working to raise awareness about Lymphoma, a group of blood cancers in the lymphatic system. The American Cancer Society estimates 89,000 people in the U.S. will be diagnosed with lymphoma in 2023. For patients with lymphoma, oncologists use technology developed by AIQ Solutions to make more confident treatment decisions, personalize care for patients, and improve treatment outcomes.

The Society of Nuclear Medicine and Molecular Imaging Fall Therapeutics Conference in Baltimore, MD is almost here. We look forward to meeting with you to discuss our solutions. Reach out today to schedule a meeting at https://www.aiq-solutions.com/contact/